SRx-T001

SRx-T001 is an investigational gene therapy developed by Sania Therapeutics for the treatment of spasticity and muscle spasm. It utilizes an intramuscular injection of an adeno-associated virus (AAV) vector to deliver a gene therapy payload, combined with oral medication, to selectively reduce excitability in targeted motor neurons. The approach aims to provide titratable and cell-type specific control over neuronal activity, potentially offering a novel therapeutic option for neurological diseases characterized by abnormal neural circuit excitability such as spasticity. As of April 2025, SRx-T001 is in preclinical development[1][2][3].